Skip to main content
. 2022 Jan 19;13(2):225–240. doi: 10.1007/s13300-021-01201-z

Table 2.

Appropriate prescribing of oral semaglutide in patients with type 2 diabetes

graphic file with name 13300_2021_1201_Tab2_HTML.jpg

ASCVD atherosclerotic cardiovascular disease, CVD cardiovascular disease, DKA diabetic ketoacidosis, eGFR estimated glomerular filtration rate, NYHA New York Heart Association, TIA transient ischemic attack, T2D type 2 diabetes